These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21266068)

  • 1. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
    Torti C; d'Arminio-Monforte A; Pozniak AL; Lapadula G; Cologni G; Antinori A; De Luca A; Mussini C; Castagna A; Cicconi P; Minoli L; Costantini A; Carosi G; Liang H; Cesana BM;
    BMC Infect Dis; 2011 Jan; 11():23. PubMed ID: 21266068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.
    Bunupuradah T; Puthanakit T; Fahey P; Kariminia A; Yusoff NK; Khanh TH; Sohn AH; Chokephaibulkit K; Lumbiganon P; Hansudewechakul R; Razali K; Kurniati N; Huy BV; Sudjaritruk T; Kumarasamy N; Fong SM; Saphonn V; Ananworanich J;
    Antivir Ther; 2013; 18(4):591-8. PubMed ID: 23296119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
    Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
    Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
    J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides.
    Barreiro P; Soriano V; Casas E; González-Lahoz J
    AIDS; 2002 Jan; 16(2):245-9. PubMed ID: 11807309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
    Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA
    HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.
    Calmy A; Petoumenos K; Lewden C; Law M; Bocquentin F; Hesse K; Cooper D; Carr A; Bonnet F;
    HIV Med; 2007 Apr; 8(3):171-80. PubMed ID: 17461861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.
    Samri A; Goodall R; Burton C; Imami N; Pantaleo G; Kelleher A; Poli G; Gotch F; Autran B
    Antivir Ther; 2007; 12(4):553-8. PubMed ID: 17668564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
    Salata RA; Grinsztejn B; Ritz J; Collier AC; Hogg E; Gross R; Godfrey C; Kumarasamy N; Kanyama C; Mellors JW; Wallis CL; Hughes MD;
    AIDS Res Ther; 2023 Jan; 20(1):3. PubMed ID: 36604746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
    Fischl MA
    AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.
    Waters L; Bansi L; Asboe D; Pozniak A; Smit E; Orkin C; Fearnhill E; Dunn D; Phillips A; ;
    Antivir Ther; 2013; 18(2):213-9. PubMed ID: 23653911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials.
    Yazdanpanah Y; Sissoko D; Egger M; Mouton Y; Zwahlen M; Chêne G
    BMJ; 2004 Jan; 328(7434):249. PubMed ID: 14742351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.